This study evaluated the long-term safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. A total of 684 participants completed a 24-week double-blind core phase before entering a 52-week open-label extension. Improvements in sexual desire were sustained, with FSFI-desire scores
